This inventor holds 1 USPTO granted patent. Top assignee: The General Hospital Corporation. Active years: 2006.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2006
Title: Wilfried Reichardt: Innovator in Gene Delivery Systems
Introduction
Wilfried Reichardt is a notable inventor based in Munich, Germany. He has made significant contributions to the field of gene delivery through his innovative research and development of hyperbranched dendron polymers. His work focuses on creating efficient and low-toxicity systems for gene therapy applications.
Latest Patents
Reichardt holds a patent for a hyperbranched dendron and methods of synthesis and use thereof. This patent describes the synthesis of hyperbranched dendron (HD) polymers using low molecular weight polyethyleneimine (BPEI-L) as a core. These polymers are designed for gene delivery, exhibiting low toxicity and effective gene transfer at low nitrogen-to-phosphate (N/P) ratios. The extensive branching of the polymer allows it to condense plasmid DNA into nanostructure complexes that are stable and efficient in transfecting cells, even in the presence of serum. In vivo studies using bioluminescent imaging have demonstrated gene expression in the liver and submandibular lymph nodes of live mice.
Career Highlights
Wilfried Reichardt is associated with The General Hospital Corporation, where he continues to advance his research in gene delivery systems. His innovative approach to polymer synthesis has positioned him as a key figure in the field of biomedical engineering.
Collaborations
Reichardt has collaborated with notable researchers such as Pallab Banerjee and Ralph Weissleder. These collaborations have further enhanced the impact of his work in the scientific community.
Conclusion
Wilfried Reichardt's contributions to the development of hyperbranched dendron polymers represent a significant advancement in gene delivery technology. His innovative research continues to pave the way for future breakthroughs in gene therapy applications.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
